{
    "nct_id": "NCT05375955",
    "official_title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Presence of skin comorbidities that would interfere with study assessment or response to treatment\n* Psychiatric condition including recent or active suicidal ideation or behavior\n* Current or recent history of severe, progressive, or uncontrolled disease\n* A history of systemic, chronic or acute skin infection requiring hospitalization, parenteral antimicrobial therapy, or is judged clinically significant.\n* Recent, significant trauma or major surgery\n* History of cancer or have undergone treatment for any type of cancer, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ with no evidence of recurrence.\n* History of angioedema or anaphylaxis to topical products or known sensitivity to any of the components of the investigational products.\n* Use of any prohibited concomitant medication(s)\n* Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).\n* Participants with an estimated glomerular filtration rate (eGFR) of <40 mL/min/1.73m2 calculated using the serum creatinine-based Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula for adults and serum creatinine >1.5 x upper limit of normal (ULN) in adolescents (12-18 years old)\n* Participants with total bilirubin ≥2x ULN (≥3 x ULN for Gilbert's disease), aspartate aminotransferase (AST) ≥2.5 x ULN, ALT ≥2.5 x ULN.\n* Clinically relevant abnormal baseline standard 12-lead electrocardiogram (ECG) including, but not limited to QTC corrected using Fridericia's Formula (QTcF) interval >450 msec and QRS > 120 msec\n* A recent history of alcohol or substance abuse",
    "miscellaneous_criteria": "Inclusion Criteria for AD population:\n\n* Diagnosis of Atopic Dermatitis (AD) for at least 3 months\n* Investigator's Global Assessment (IGA) score of 2 (mild), or 3 (moderate)\n* AD covering 5% and up to 40% of Body Surface Area (BSA)\n* A Peak Pruritus Numerical Rating Scale (PP-NRS) average score of ≥2\n\nInclusion Criteria for Plaque Psoriasis\n\n* Diagnosis of Plaque Psoriasis (PsO) for at least 6 months\n* Physician Global Assessment (PGA) score of 2 (mild), 3 (moderate), or 4 (severe)\n* PsO covering 2% to 20% (inclusive) of BSA"
}